LifeTech Scientific Corporation published its 2025 Environmental, Social and Governance (ESG) report, detailing continued product innovation, deeper international penetration and the company’s first medium- to long-term carbon roadmap. The reporting boundary covers R&D, manufacturing and commercial operations in Shenzhen and Dongguan as well as overseas subsidiaries for the year ended 31 December 2025.
Product & R&D Highlights • 2025 saw the domestic launch and NMPA approvals for several flagship endovascular devices, including the Thoracoabdominal™ Branch-G Stent Graft System and SilverFlow™ PV Peripheral Vascular Stent System. • The Ankura™ TAA IIc Stent Graft secured EU Medical Device Regulation (MDR) CE certification; multiple additional stent, occluder and catheter platforms advanced in China and Europe, and the Congenital Heart Defect Occluder became LifeTech’s 16th product admitted to the NMPA’s Special Approval Procedure for Innovative Medical Devices. • The iron-based Sirolimus-Eluting IBS™ Bioresorbable Coronary Scaffold completed three-year follow-up of its Phase III clinical study, and Titan™ Peripheral Bioresorbable Scaffold initiated registration in China and Europe. • The company’s interventional technology projects collected top-tier national awards, including First Prize at the Chinese Medical Science & Technology Awards and recognition from provincial authorities.
Operational & Market Development • While consolidating its leading position in China, the company reported “considerable and sustained” overseas revenue growth and continued to refine its global distribution network across Europe, Southeast Asia, Latin America and the Middle East.
Governance & Compliance • An ESG governance structure comprising the Board, an ESG Committee and an ESG Taskforce was fully operational. • No cases of anti-corruption, anti-bribery or anti-competitive behaviour were recorded; all employees received compliance training, totalling 320.6 hours for anti-corruption alone.
Human Capital • Headcount stood at 1,202 (49 % female) at year-end 2025. • Average training hours reached 28.1 per employee, with 95 % of staff receiving training during the year. • Employee turnover was 27.1 % (326 employees), and there were no work-related fatalities or injuries.
Environmental Performance & Targets • Scope 1 emissions: 1,858.3 tCO₂e; Scope 2 emissions: 5,981.5 tCO₂e; total Scope 1+2 fell to 7,839.8 tCO₂e, a 2.5 % reduction versus 2024. • Energy consumption totalled 23,709.8 MWh, while water use reached 147,627 tonnes. • LifeTech committed to cutting its GHG intensity (tCO₂e/m²) by 5 % between 2024 and 2030, peaking carbon emissions by 2030 and achieving carbon neutrality by 2050 through process optimisation, green manufacturing and renewable-energy adoption.
Looking Ahead Management reiterated the “dual-engine” strategy of innovation and internationalisation. Priorities for 2026 include accelerating commercialisation of advanced stent graft platforms, broadening overseas market penetration and embedding climate-related considerations into strategic planning and risk management.